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Key Points
• The integration of mutations
and cytogenetic lesions im-
proves the accuracy of sur-
vival prediction in chronic lym-
phocytic leukemia.
The identification of new genetic lesions in chronic lymphocytic leukemia (CLL) prompts
a comprehensive and dynamic prognostic algorithm including gene mutations and
chromosomal abnormalities and their changes during clonal evolution. By integrating
mutational and cytogenetic analysis in 1274 CLL samples and using both a training-
validation and a time-dependent design, 4 CLL subgroups were hierarchically classified:
(1) high-risk, harboring TP53 and/or BIRC3 abnormalities (10-year survival: 29%);
(2) intermediate-risk, harboring NOTCH1 and/or SF3B1 mutations and/or del11q22-q23
(10-year survival: 37%); (3) low-risk, harboring 12 or a normal genetics (10-year
survival: 57%); and (4) very low-risk, harboring del13q14 only, whose 10-year survival (69.3%) did not significantly differ from a
matched general population. This integrated mutational and cytogenetic model independently predicted survival, improved CLL
prognostication accuracy compared with FISH karyotype (P < .0001), and was externally validated in an independent CLL cohort.
Clonal evolution from lower to higher risk implicated the emergence of NOTCH1, SF3B1, and BIRC3 abnormalities in addition to
TP53 and 11q22-q23 lesions. By taking into account clonal evolution through time-dependent analysis, the genetic model
maintained its prognostic relevance at any time from diagnosis. These findings may have relevant implications for the design of
clinical trials aimed at assessing the use of mutational profiling to inform therapeutic decisions. (Blood. 2013;121(8):1403-1412)
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2. Describe the ability of this integrated mutational and cytogenetic model to predict survival and prognosis.
3. Describe clonal evolution in this model and its effect on predicting prognosis.
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Introduction
The course of chronic lymphocytic leukemia (CLL) ranges from
very indolent with a nearly normal life expectancy to rapidly
progressive leading to early death.1,2 To better understand the
genetic basis of CLL heterogeneity and improve prognostication of
patients, all recurrent and clinically relevant molecular lesions
should be combined into a comprehensive prognostic model.
Chromosomal aberrations and TP53 mutations are of key
importance for predicting CLL outcome.3,4 Recently, next-
generation sequencing has disclosed a further degree in the
molecular complexity of CLL by revealing novel genetic lesions
affecting the NOTCH1, SF3B1, MYD88, and BIRC3 genes.5-9
Alterations of these genes occur in approximately 5%-10% of CLL
patients at diagnosis and, in the case of NOTCH1, SF3B1, and
BIRC3, have shown significant correlations with survival in
consecutive series from independent institutions.5-11 These findings
prompt the integration of the newly discovered genetic lesions into
a model based on both chromosomal abnormalities and gene
mutations.
Available genetic prognostic models in CLL are based on the
evaluation of risk factors detected at a specific time point.3-4 The
appearance of additional genetic lesions during CLL course may
dynamically modify patient survival, as suggested by the associa-
tion between clonal evolution and poor prognosis, treatment
resistance, and transformation.12-22 On these bases, a dynamic
prognostic model based on a time-dependent analysis of CLL
genetic lesions may prove useful for a better understanding of
disease outcome. In the present study, we report an integrated
mutational and cytogenetic model for CLL survival prediction that
maintains its prognostic relevance in a time-dependent fashion.
Methods
Patients
Time-fixed analysis at diagnosis was based on a training series of 637 newly
diagnosed and previously untreated CLL patients of whom 583 (91.5%)
were provided with regular follow-up. Among CLL from the training series
that required treatment, 122 of 266 (45.8%) patients received rituximab-
based regimens (ie, fludarabine-cyclophosphamide-rituximab, fludarabine-
rituximab, or pentostatin-cyclophosphamide-rituximab), 64 of 266 (24.0%)
received fludarabine-based regimens (ie, fludarabine or fludarabine-
cyclophosphamide), and 80 of 266 (30.1%) received alkylator-based
regimens (ie, chlorambucil). To externally validate the results of the
time-fixed analysis, an independent cohort of 370 newly diagnosed and
previously untreated CLL patients was also investigated. Time-dependent
analysis and analysis of clonal evolution were based on a single-institution
cohort of 257 CLL patients of the training series with sequential tumor
samples (n 469) and clinical information prospectively collected at
clinically relevant time points (ie, at diagnosis, progression, and last
follow-up). Further details of the study populations are available in
supplemental Table 1 and supplemental Methods (available on the Blood
Web site; see the Supplemental Materials link at the top of the online
article). CLL diagnosis was according to 2008 International Workshop on
Chronic Lymphocytic Leukemia-National Cancer Institute criteria (IWCLL-
NCI) and confirmed by a flow cytometry score  3 in all cases.2
Monoclonal B-cell lymphocytosis were excluded. The study was approved
by the institutional ethical committee (protocol code 59/CE; study number
CE 8/11). Patients provided informed consent in accordance with local
institutional review board requirements and the Declaration of Helsinki.
Samples
Overall, 1274 CLL samples were subjected to mutational and FISH
analysis. CLL samples were extracted from fresh or frozen PBMCs isolated
by Ficoll-Paque gradient centrifugation. In all cases, the fraction of tumor
cells corresponded to  70% as assessed by flow cytometry. Matched
normal DNA from the same patient was obtained from saliva or from
purified granulocytes and was confirmed to be tumor-free by PCR of
tumor-specific IGHV-D-J rearrangements. High-molecular-weight genomic
DNA was extracted from tumor and healthy samples according to standard
procedures. DNA was quantified by the NanoDrop 2000C spectrophotom-
eter (Thermo Scientific).
Molecular studies
The mutation hot spots of the TP53 (exons 4-9, including splicing sites;
RefSeq NM_000546.5), NOTCH1 (exon 34; including splicing sites;
RefSeq NM_017617.2), SF3B1 (exons 14, 15, 16, 18, including splice sites;
RefSeq NM_012433.2), MYD88 (exons 3, 5, including splicing sites;
RefSeq NM_002468.4), and BIRC3 (exons 6-9, including splicing sites;
RefSeq NM_001165.4) genes were analyzed by PCR amplification and
DNA direct sequencing of high-molecular-weight genomic DNA.8,10,11 The
mutant allele frequency was estimated by next-generation sequencing.5
Amplicons known to harbor TP53, NOTCH1, SF3B1, MYD88, or BIRC3
mutations by Sanger sequencing were reamplified from genomic DNA by
oligonucleotides containing the gene-specific sequences, along with the
10-bp MID tag for multiplexing and amplicon library A and B sequencing
adapters. The obtained amplicon library was subjected to deep sequencing
on the Genome Sequencer Junior instrument (454 Life Sciences).5 To obtain
approximately 700-fold coverage per amplicon, no more than 100 amplicons/
run were analyzed. The obtained sequencing reads were mapped to
reference sequences and analyzed by the Amplicon Variant Analyzer
Version 2.7 software (Roche) to establish the mutant allele frequency.
Probes used for FISH analysis were: (1) LSID13S319, CEP12, LSIp53, and
LSIATM (Abbott) and (2) RP11-177O8 (BIRC3) BAC clone.11 Further
details of the molecular studies are available in supplemental Methods.
Statistical analysis
Overall survival (OS) was the primary end point and was measured from the
date of initial presentation to the date of death from any cause (event) or last
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follow-up (censoring). Treatment-free survival was measured from date of
initial presentation to date of progressive disease requiring treatment
according to IWCLL-NCI guidelines (event), death or last follow-up
(censoring).2 Survival analysis was performed by the Kaplan-Meier method.
The crude and adjusted association between time-fixed exposure variables
at diagnosis and OS was estimated by Cox regression. The stability of the
Cox model was internally validated using bootstrapping procedures.23,24
Recursive partitioning was applied to divide patients in genetic subgroups
with different outcome.25 The stability of the recursive decision tree was
validated by the random survival forest method.26 An amalgamation
algorithm was used to merge terminal nodes showing homogenous
survival.25 Relative survival, defined as the ratio between the actuarial
survival observed in the CLL cohort and the expected survival of the
general Italian population matched to CLL patients by sex, age, and
calendar year of diagnosis, was calculated using the Ederer II method. Time
to acquisition of a risk factor was estimated considering death as a
competing risk and was compared across groups with the Gray test. The
crude and adjusted effect of time-varying prognostic factors was assessed
by time-dependent Cox regression. Landmark analysis was used to
illustrate the effect of time-varying prognostic factors. Associations and
anti-associations between genetic lesions were assessed by Fisher exact test
corrected for multiple comparisons by the Bonferroni test. The number of
cases (n  637) allowed us to identify all possible cooccurring genetic
lesions in the study and exclusive alterations in genetic lesions that occurred
in at least 8.6% of cases. Categorical variables were compared by 2 test
and Fisher exact test when appropriate. Continuous variables were com-
pared by Mann-Whitney (2 unrelated samples) or Wilcoxon (2 related
samples) tests. All statistical tests were 2-sided. Statistical significance was
defined as P  .05. The analysis was performed with SPSS Version
20.0 and R Version 2.15.1 (http://www.r-project.org) software. Further
details of the statistical analysis are available in supplemental Methods.
Results
Mutational complementation groups and independent
prognostic value of genetic lesions in newly diagnosed CLL
patients
As a preliminary step toward the construction of an integrated
mutational and cytogenetic model, we assessed the prevalence and
independent prognostic value of the candidate genetic lesions in the
training series of 637 CLL patients (supplemental Tables 1-3).
Del13q14 and 12 distributed in a mutually exclusive fashion
(P  .0001; supplemental Figures 1 and 2). With the sole exception
of the expected association between NOTCH1 mutations and
12 CLL (P  .0014),27,28 the prevalence of other genetic lesions
did not differ among molecular subgroups (supplemental Figures
1 and 2). Consistent with a dual hit mechanism of inactivation,
mutations of both TP53 and BIRC3 frequently cooccurred with deletion
of the corresponding locus (P .0001 and P .0065, respectively;
supplemental Figures 1 and 2).
Analysis of FISH abnormalities reproduced the previously
described prognostic groups in this study cohort (supplemental
Figure 3 and supplemental Table 3).3 Patients harboring del17p13 and
TP53 mutations in the absence of del17p13 showed an identical
outcome in the study cohort and therefore were combined for the
analysis of outcome.13 Among new CLL lesions, survival analysis
confirmed the independent prognostic value of NOTCH1, SF3B1,
and BIRC3 abnormalities (supplemental Table 3). MYD88 muta-
tions had no prognostic effect (P  .1728), although the study was
adequately powered (90%) for detecting the impact of these
low-frequency (approximately 4%) mutations on survival.
This preliminary assessment provided the rationale for includ-
ing alterations of NOTCH1, SF3B1, and BIRC3 in addition to
standard FISH lesions and TP53 mutations in the subsequent
development of an integrated mutational and cytogenetic model.
Integrated mutational and cytogenetic model for CLL
prognostication
The hierarchical order of relevance of the genetic lesions in
predicting CLL survival was established by recursive partitioning
analysis of the training series (Figure 1).25,26 TP53 disruption was
the most predictive genetic variable in the survival tree, followed
by BIRC3 disruption, mutations of SF3B1 and NOTCH1, and the
del11q22-q23 mutation (Figure 1). In CLL patients lacking these
abnormalities, 12 and del13q14 further stratified outcome. Mea-
surement of the variable importance validated the hierarchical
order of relevance of the genetic lesions established by the
recursive partitioning analysis and confirmed the stability of the
decision tree (supplemental Table 4).26 Based on the application of
the amalgamation algorithm to the terminal nodes,25 cases harbor-
ing TP53 abnormalities and cases harboring BIRC3 abnormalities
were grouped into a single category, as well as cases harboring
NOTCH1 mutations, SF3B1 mutations, or the del11q22-q23 muta-
tion. This approach allowed us to establish an integrated mutational
and cytogenetic model for classifying newly diagnosed CLL
patients according to risk of death.
Four CLL subgroups were classified hierarchically (Figure 2).
The high-risk category included patients harboring TP53 disruption
and/or BIRC3 disruption independent of cooccurring lesions (5-year OS:
50.9%; 10-year OS: 29.1%; Figure 2A). When the demographic effects
of age, sex, and year of diagnosis were compensated, the 10-year life
expectancy of high-risk patients was only 37.7% of that expected in
the matched general population (P  .0001; Figure 3B).
The intermediate-risk category included patients harboring
NOTCH1 and/or SF3B1 mutations and/or del11q22-q23 in the
absence of TP53 and BIRC3 abnormalities (5-year OS: 65.9%;
10-year OS 37.1%; Figure 2A). The 10-year life expectancy of
intermediate-risk patients was only 48.5% of that expected in the
matched general population (P  .0001; Figure 3B).
The low-risk category (5-year OS: 77.6%; 10-year OS: 57.3%)
comprised both patients harboring 12 and patients wild-type for
all genetic lesions (ie, healthy patients; Figure 2A). Despite
experiencing an indolent behavior, the 10-year life expectancy of
low-risk patients was 70.7% of that expected in the matched
general population (P  .0001; Figure 3B).
The very low-risk category included patients harboring del13q14
as the sole genetic lesion (5-year OS: 86.9%; 10-year OS 69.3%;
Figure 2A). The 10-year life expectancy of very low-risk patients
was only slightly (84.2%) and was not significantly (P  .1455)
lower than that expected in the matched general population (Figure
3B). Consistent with the small excess mortality experienced by
very low-risk CLL patients compared with the matched general
population, the cause of death in this subgroup was unrelated to
CLL in many patients (16 of 27, 59.2%). In the remaining patients,
the cause of death was second cancer (4 of 27, 14.8%), infection
(4 of 27, 14.8%), and progressive CLL (3 of 27, 11.1%).
Differences in outcome among the 4 subgroups were consistent
with differences in the prevalence of unfavorable clinical and biologic
features at presentation (supplemental Table 5) and differences in
disease progression as indicated by treatment-free survival (Figure 2B).
Because the higher-risk genetic groups contained more patients
with advanced-stage disease, we also limited the survival analysis
to Rai stage 0-I CLL. Consistent with the results obtained in the
whole CLL population, the genetic model also stratified 4 genetic
subgroups in early-stage CLL (supplemental Figure 4).
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To provide a preliminary signal on the reproducibility of the
prognostic model in patients treated with rituximab-containing
regimens, we analyzed the impact of the model on: OS from
presentation in patients from the training series who received the
diagnosis in 2005 or afterward29 (in this time frame, 67.5% of cases
requiring treatment received rituximab-based regimens) and
OS from first treatment in a consecutive single-institution cohort of
62 patients who received fludarabine-cyclophosphamide-rituximab
and were provided with tumor samples and clinical information
prospectively collected at first progression. Consistent with the
results obtained in the whole CLL population, the genetic model also
stratified 4 genetic subgroups in these patients (supplemental Figure 5).
These data establish the hierarchical order of relevance of
recurrent mutations and cytogenetic lesions in CLL and identify
4 distinct prognostic subgroups.
The integrated mutational and cytogenetic model is an
independent and reproducible predictor of OS in CLL
Multivariate analysis selected the genetic model as an independent
risk factor of OS in the training series (ptrend  0.0010), along with
age (P  .0001), Rai stage (ptrend  0.0001), and unmutated IGHV
genes (P  .0036; Table 1). Internal validation on 1000 bootstrap
samples confirmed the stability of the genetic model as a prognostic
factor for OS in the training series (Table 1).
Survival analysis in an independent external validation series of
370 newly diagnosed CLL patients confirmed: (1) the more general
reproducibility of the genetic model in predicting OS (supplemen-
tal Figure 6), (2) its capacity of discriminating patient outcome
(c-index in the validation series was 0.662 vs 0.642 in the training
series), and (3) its independent prognostic value (ptrend 0.0053) when
adjusted for other confounding covariates (supplemental Table 6).
Based on these data, the genetic model represents one of the
most important independent prognosticators of CLL survival in
both the training and the validation cohorts.
Inclusion of mutations in addition to FISH abnormalities
significantly improves the accuracy of CLL prognostication
Overall, approximately 20% (105 of 488) of lower risk patients
according to the FISH cytogenetic model,3 including 20.1% (39 of
194) del13q14-only CLL, were reclassified into higher-risk sub-
groups by the integrated mutational and cytogenetic model because
of the cooccurrence of NOTCH1, SF3B1, and TP53 mutations or
Figure 1. Decision tree resulting from recursive partitioning analysis and amalgamation in the training series. Disruption of TP53 and BIRC3, mutations of SF3B1 and
NOTCH1, and del11q22-q23 were the factors selected by the algorithm to split the patient population in 6 terminal nodes. Presence or absence of the TP53 disruption
independent of cooccurring genetic lesions was the most significant covariate for the entire study population. Among patients lacking TP53 abnormalities, the most significant
covariate was BIRC3 disruption. Among patients lacking both TP53 and BIRC3 abnormalities, the most significant covariate was SF3B1 mutation status. Among patients
lacking TP53, BIRC3, and SF3B1 lesions, the most significant covariate was NOTCH1 mutation status. Among patients lacking TP53, BIRC3, SF3B1, and NOTCH1 lesions,
the most significant covariate was del11q22-q23. Based on the application of the amalgamation algorithm to the terminal nodes, patients harboring TP53 abnormalities and
those harboring BIRC3 abnormalities were grouped into a single category, as well as patients harboring NOTCH1 mutations, SF3B1 mutations, or del11q22-q23. Genetic
lesions are represented from right to left according to their hierarchical order of relevance in splitting the parent node into daughter nodes with significantly different survival
probabilities. The P value corresponds to the log-rank test adjusted for multiple comparisons. The right branch of each split represents the presence of the lesion. The left
branch of each split represents the absence of the lesion. The Kaplan-Meier curves estimate the OS of patients belonging to each terminal node. N indicates the number of
patients in the node; M, mutation; and DIS, disruption.
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BIRC3 disruption (supplemental Table 7). Consistently, the inclu-
sion of TP53, NOTCH1, and SF3B1 mutations and of BIRC3 lesions in
addition to FISH abnormalities significantly improved the accuracy of
survival prediction (c-index: 0.617 vs 0.642; P  .0001; Figure 3).
Based on the sole FISH assessment, the life expectancy of
del13q14-only CLL patients was significantly lower (68.1% at
10 years; P  .0001) than that expected in the matched general
population (Figure 3A). Conversely, the genetic model segregated a
subgroup of patients with del13q14 only who lacked other genetic
alterations and showed an expected survival not significantly different
from that of the matched general population (Figure 3B). This subgroup
of del13q14-only CLLpatients displayed a preferential usage of mutated
IGHV genes (80.9% vs 42.1% in del13q14 CLL with cooccurring
mutations).
We conclude that integrating mutations and cytogenetic lesions
proves useful in refining the prognosis of CLL and helps to identify
a subgroup of patients with extremely indolent disease.
Assessment of clonal evolution in CLL by integrated
mutational and cytogenetic analysis
To clarify the evolution of NOTCH1, SF3B1, and BIRC3 lesions,
we repeatedly analyzed CLL patients provided with 2 sequential
samples (n 202) followed for at least 2 years after presentation
(median interval between baseline and last sequential sample:
62.8 months; range, 24-150 months). FISH lesions and
TP53 mutations were also investigated.
Overall, 36 (17.8%) of the sequentially investigated patients
developed 59 new genetic lesions during disease course, mainly
represented by TP53, NOTCH1, SF3B1, BIRC3, and del11q22-
q23 abnormalities (54 of 59, 91.5%; supplemental Tables 8 and 9).
The median time to clonal evolution was 3 years (95% confidence
interval [CI], 1.9-4.0). The median follow-up of patients who
developed clonal evolution was 6.1 years (95% CI, 4.9-7.4 years).
The median follow-up of patients who did not develop clonal
evolution was 5.3 years (95% CI, 4.8-5.7 years). No patient
developed a new 12 or a new monoallelic del13q14, whereas
development of biallelic del13q14 (ie, new del13q14 on the second
chromosome after initially monoallelic del13q14) was restricted to
4 (1.9%) patients.
Among cases that were informative at presentation, TP53,
NOTCH1, SF3B1, MYD88, and BIRC3 mutant allele frequency did
not significantly change during disease course (supplemental
Figure 7). Clonal fluctuation, defined as the disappearance of a
mutated clone, occurred in only 3 patients; in all 3, the baseline
mutated clone was substituted by a second clone harboring a new
high-risk mutation (supplemental Figure 8 and supplemental Table 8).
These data document that, like TP53 abnormalities and del11q22-
q23, also NOTCH1, SF3B1, and BIRC3 lesions may emerge during
clonal evolution.
Baseline factors associated with high-risk clonal evolution
To investigate the dynamics of acquisition of high-risk genetic
lesions during follow-up, we evaluated the time to clonal evolution
and its modifications according to disease characteristics at diagno-
sis after adjusting for death as a competing risk.
At 10 years from diagnosis, 24.5% of CLL patients belonging to
the very-low- and low-risk genetic subgroups had developed new
Figure 2. Kaplan-Meier estimates of OS and treatment-free survival according to the integrated mutational and cytogenetic model in the training series.
(A) OS. (B) Probability of progressive disease requiring treatment according to IWCLL-NCI guidelines as indicated by treatment-free interval. Cases harboring TP53 and/or
BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by the red line. Patients harboring NOTCH1 mutations (NOTCH1 M)
and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented by the yellow line. Patients harboring 12 in the
absence of the TP53 disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23 and patients wild-type for all genetic lesions (normal) are
represented by the green line. Cases harboring del13q14 as the sole genetic lesion are represented by the blue line. nr indicates not reached.
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TP53, NOTCH1, SF3B1, BIRC3, or del11q22-q23 lesions because
of clonal evolution and therefore were switched to a higher-risk
category in the genetic model. Clinical features at presentation
predicting the development of new high-risk genetic lesions were
age  65 years (P  .0192), high LDH (P  .0093), and unmu-
tated IGHV genes (P  .0087; Figure 4A-C).
Figure 3. Observed OS in patients from the training series compared with the expected OS in the matched general population. OS in CLL patients stratified according
to the FISH cytogenetic model (A) and the integrated mutational and cytogenetic model (B) relative to the expected OS in the age-, sex-, and calendar year of diagnosis–matched general
population (black line). (A) Patients harboring del17p13 irrespective of cooccurring cytogenetic lesions are represented by the red line. Patients harboring del11q22-q23 in the absence of
del17p13 are represented by the purple line. Patients harboring12 in the absence of del17p13 and del11q22-q23 are represented by the yellow line. Patients harboring a normal FISH
karyotype are represented by the green line. Patients harboring del13q14 deletion in the absence of other cytogenetic abnormalities are represented by the blue line. (B) Patients harboring
TP53 and/or BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by the red line. Patients harboring NOTCH1 mutations (NOTCH1 M)
and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented by the yellow line. Patients harboring12 in the absence of TP53
disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23, and patients wild-type for all genetic lesions (normal) are represented by the green line. Patients
harboring del13q14 as the sole genetic lesion are represented by the blue line.
Table 1. Time-fixed univariate and multivariate analysis of OS in the CLL training series
Univariate analysis Multivariate analysis
Internal bootstrapping validation
Bootstrap parameters (mean) Bootstrap
selectionHR LCI UCI P HR LCI UCI P HR LCI UCI
Age, y* 1.06 1.04 1.07  .0001 1.06 1.04 1.07  .0001 1.06 1.04 1.97 100%
Sex
Female 1.00 .0138 1.00 .1962 1.00
Male 1.47 1.08 2.00 1.23 0.89 1.71 1.27 0.91 1.77 50%
Rai stage
0-I 1.00  .0001† 1.00  .0001† 1.00
II 1.82 1.19 2.77 1.46 0.95 2.25 1.48 0.95 2.30 100%
III-IV 4.19 2.99 5.87 3.08 2.16 4.39 3.33 2.31 4.79 100%
IGHV homology 98% 1.00  .0001 1.00 .0036 1.00
IGHV homology 98% 2.18 1.61 2.94 1.63 1.17 2.28 1.68 1.20 2.37 94.9%
Integrated mutational
and cytogenetic model
Very-low risk 1.00  .0001† 1.00 .0010† 1.00
Low-risk 1.57 1.00 2.50 1.20 0.75 1.94 1.23 0.76 2.01 97.3%
Intermediate-risk 2.70 1.66 4.40 1.98 1.19 3.32 2.06 1.22 3.51 97.3%
High-risk 4.29 2.71 6.79 2.34 1.41 3.89 2.46 1.47 4.14 97.3%
Shrinkage coefficient 0.97; discrimination: bias-corrected c-index, 0.762; optimism, 0.005; calibration: bias-corrected calibration slope, 0.965; optimism, 0.035.
HR indicates hazard ratio; LCI, 95% lower CI; UCI, 95% upper CI; and IGHV, immunoglobulin heavy variable gene.
*Analyzed as a continuous variable.
†P for trend.
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Consistent with their inferior OS probability, patients belonging
to the low-risk subgroup according to the genetic model (ie, those
harboring 12 or normal genetics) showed a significantly higher
probability of developing poor-risk genetic lesions and of being
changed to the intermediate- or high-risk subgroups compared with
very-low-risk CLL patients harboring del13q14 only (P  .0435;
Figure 4D). The increased risk of clonal evolution in patients
harboring 12 or a normal genotype may be explained by the
higher prevalence of unmutated IGHV genes (supplemental Table 5) and
the higher risk of treatment requirement (Figure 2) compared with
del13q14-only CLL patients.
Impact of high-risk clonal evolution on CLL survival
In traditional Kaplan-Meier or Cox regression analysis, a risk
factor measured at baseline is usually related to mortality thereaf-
ter. However, the development of poor-risk factors during disease
course may substantially modify patient outcome and estimates of
prognosis should improve if such time-dependent changes are
taken into account. Therefore, we investigated whether the assess-
ment of clonal evolution contributes to improve OS prediction
using a time-dependent Cox regression analysis. This analysis
included variables considered “fixed” in time (ie, sex and IGHV
mutation status) and time-varying variables (ie, age, Rai stage, and
status of the genetic lesions) that were repeatedly assessed at
clinically relevant time points (ie, disease progression or last
follow-up).
Time-varying genetic lesions associated with short OS were
TP53 disruption (P  .0001), BIRC3 disruption (P  .0166), and
NOTCH1 mutations (P  .0247). SF3B1 mutations were of border-
line significance (P  .0766; supplemental Table 10). Dynamic
changes of the genetic model due to clonal evolution retained a
statistically significant impact on OS (ptrend  0.0003) that was
independent of modifications affecting other time-varying factors
such as age and disease stage (supplemental Table 11). Consis-
tently, the genetic model stratified CLL patient OS at 1, 2, and
4 years from diagnosis by landmark analysis (Figure 5).
These results document the prognostic relevance of developing
high-risk genetic lesions during CLL course and show that the genetic
model maintains its prognostic impact at any time from diagnosis.
Discussion
In the present study, we provide an integrated mutational and cytoge-
netic model for CLL prognostication that: (1) allows the segregation of
4 patient subgroups with distinct risks of death in a fashion that is
reproducible and independent from other well-established prognostica-
tors, (2) takes into account clonal evolution, and (3) maintains its
independent prognostic relevance at any time point from diagnosis.
In terms of discriminating patient course, the integrated muta-
tional and cytogenetic model significantly adds to the model based
solely on FISH karyotype.3 Because of the cooccurrence of
Figure 4. Cumulative incidence of high-risk clonal evolution. Time to high-risk clonal evolution was defined as the time elapsed from diagnosis to the date of development
of TP53 abnormalities, BIRC3 abnormalities, NOTCH1 mutations, SF3B1 mutations, or del1q22-q23 (events) or last follow-up or death (censoring). Analysis was performed
using death as a competing risk. Only patients who did not present high-risk abnormalities at diagnosis were included in this analysis. (A-D) Cumulative incidence of clonal
evolution according to age 65 years (hazard ratio [HR]  4.18; 95% CI, 1.26-13.8; 5-year risk: 17.1%, 10-year risk: 32.9%;), high LDH (HR  3.15; 95% CI, 1.32-7.55; 5-year
risk: 24.8%, 9-year risk: 62.8%), unmutated IGHV genes (HR  2.89; 95% CI, 1.31-6.39; 5-year risk: 18.5%, 9-year risk: 50.8%), 12 or a normal genetics (HR  2.29;
95% CI, 1.03-5.10; 5-year risk: 13.8%, 9-year risk: 34.5%).
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unfavorable mutations, approximately 20% of patients belonging
to low-risk cytogenetic subgroups were reclassified into 1 of the
2 highest-risk genetic categories. This refinement allows the
segregation of a subgroup of CLL patients harboring del13q14
only, which accounts for a relevant fraction (approximately 25%)
of newly diagnosed patients and shows an expected survival only
slightly, though not significantly, lower than that of the general
population. The small residual excess mortality observed in this
subgroup may be due to the inclusion in the case mixture of patients
harboring poor-risk genetic lesions that are currently unknown
and/or patients with a complex karyotype that was not captured by
FISH approaches.30 The very favorable outcome of del13q14-only
CLL may be explained by their slow progression rate (approxi-
mately 4% per year), documenting that del13q14-only CLL is a
highly stable clinical entity. Notably, the progression rate of
del13q14-only CLL is in the order of magnitude of that described in
other conditions considered as premalignant.31,32
Recursive partitioning allowed us to determine that SF3B1 and
NOTCH1 mutations are hierarchically classified after TP53 and
BIRC3 lesions. Consistently, patients harboring NOTCH1 or SF3B1
mutations but purged of TP53 and BIRC3 abnormalities showed an
intermediate-risk profile similar to del11q22-q23 CLL.3,33
TP53 abnormalities play a central role in our understanding of the
poor prognosis of high-risk CLL patients, but fail to explain the
molecular basis of a substantial fraction of high-risk patients.3,4,33
According to the model proposed in this study, BIRC3 abnormali-
ties complement TP53 disruption in the identification of high-risk
patients. This observation is consistent with the fact that
BIRC3 abnormalities occur in approximately 40% of chemorefrac-
tory but TP53 wild-type CLL patients but are absent in chemosen-
sitive cases.11
Even if they are absent at presentation, NOTCH1, SF3B1, and
BIRC3 lesions may emerge during disease course, thus expanding
the spectrum of genetic events currently associated with high-risk
clonal evolution that were so far limited to TP53 abnormalities and
del11q22-q23.12-22 Overall, the probability of developing new
high-risk genetic lesions is substantial (approximately 25% at
10 years), and the acquisition of high-risk genetic lesions over time
affects survival in a manner that is independent of modifications of
other time-varying factors such as patient age and disease stage. On
these bases, one additional goal of the present study was to
establish a dynamic model accounting for all prognostically
meaningful genetic lesions and their modifications during disease
course because of clonal evolution. According to this dynamic
approach, the integrated mutational and cytogenetic model retains
its prognostic relevance at any time point during the clinical course,
and the hazard of death increases any time a CLL patient shifts to a
higher-risk category of the genetic model. These results point to the
relevance of sequentially reassessing the parameters of the genetic
model when an updated genetic status is required for redefining the
precise prognosis of the patient.
The probability of undergoing clonal evolution is not uniform
across CLL patients, but varies according to patient age and
baseline features of the disease. Although IGHV mutation status
has been already associated with clonal evolution in CLL,12,34 the
relationship between aging and instability of the leukemic clone is
Figure 5. Landmark analysis of the cumulative probability of OS according to the integrated mutational and cytogenetic model. (A) Diagnosis. (B) Landmark at 1 year.
(C) Landmark at 2 years. (D) Landmark at 4 years. Patients harboring TP53 and/or BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by
the red line. Patients harboring NOTCH1 mutations (NOTCH1 M) and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented
by the yellow line. Patients harboring12 in the absence of TP53 disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23 and patients wild-type for all
genetic lesions (normal) are represented by the green line. Patients harboring del13q14 as the sole genetic lesion are represented by the blue line.
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an unexpected finding of the present study and may be related to a
decline in genomic maintenance mechanisms in older patients or a
greater propensity of elderly patients to positively select and
expand clones harboring high-risk genetic lesions.35-37
Regarding the impact on clonal evolution of the baseline
genetics of the clone, low-risk CLL patients harboring 12 or a
normal genotype at diagnosis are characterized by a approximately
2-fold higher probability of developing poor-risk genetic lesions
and of switching to the highest-risk genetic subgroups compared
with very-low-risk CLL patients harboring del13q14 only. The
relative instability of the leukemic clone in CLL with 12 or a
normal genotype might explain why these patients experience a
shorter survival compared with del13q14-only CLL.
Given the growing number of new targeted agents, the manage-
ment of CLL will conceivably be revised and early intervention
may also become an option.38,39 In this changing scenario,38,39 there
is increasing interest in the use of prognostic markers that may
guide the management of patients from the early phases of the
disease. Our findings may have relevant implications for the design
of clinical trials aimed at testing early intervention approaches. In fact,
very-low-risk cases harboring del13q14 only may not gain any addi-
tional benefit from early treatment because of their indolent course, low
risk of clonal evolution, and nearly normal life expectancy.
These data show that the integrated mutational and cytogenetic
model can classify CLL patients into more precise subgroups,
advance our understanding of the molecular heterogeneity of CLL,
and improve current prognostic algorithms. Future challenges are
to design rapid and affordable molecular assays and to define
prospectively whether specific treatments may overcome the poor
prognosis conferred by higher-risk lesions.
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